Revolution Medicines (NASDAQ:RVMD) just picked up a partner with deep pockets and a presence across Asia. On August 10, the company announced a multi-part collaboration with BeOne Medicines, pairing clinical development with a regional rights deal. For a stock that has already climbed more than 400% over the past year, the question is whether this partnership adds real fuel or just more expectations to live up to.
Bull Case: A Partner That Shares The Load
The collaboration works on two tracks. First, a clinical partnership will test combinations of BeOne’s oncology assets alongside all four of Revolution Medicines’ clinical-stage RAS(-ON) inhibitors: daraxonrasib, zoldonrasib, elironrasib, and RMC-5127. Planned studies will pair BeOne’s PRMT5 inhibitor BGB-58067 and its trispecific antibody BG-T187 with either daraxonrasib or zoldonrasib, opening new combination pathways for RAS addicted cancers. Second, a separate rights agreement hands BeOne exclusive development and commercialization rights to those same four inhibitors in select Asian markets, while Revolution Medicines keeps rights everywhere else, including Japan and South Korea.
In exchange, Revolution Medicines gets milestone payments and tiered royalties on regional sales, and BeOne will fund and run a global Phase 3 study for one of the inhibitors, effectively sharing the cost of getting a drug across the finish line. That matters because the science underneath is already compelling. Daraxonrasib targets RAS, a protein long considered undruggable because its mutant form gets stuck switched on and drives tumor growth. In April, Revolution Medicines reported that patients with previously treated metastatic pancreatic cancer taking daraxonrasib had a median overall survival of 13.2 months, nearly double what chemotherapy delivered. The drug is also in late-stage trials for non-small cell lung cancer, a second front that could widen its addressable market well beyond pancreatic cancer.
Bear Case: A Price Tag That Assumes A Lot
None of this comes cheap. Revolution Medicines carries a market capitalization around $40 billion with no approved product generating sales yet, and daraxonrasib is still awaiting decisions from both the FDA and European regulators. Street’s own consensus peak sales projections for the drug range from $5 billion to $7.6 billion, and even the low end of that range implies the stock trades at roughly eight times sales that do not exist today. One analysis covering the stock argued that, after such a sharp runup, other growth names now offer a more attractive balance of risk and reward. The BeOne deal also only covers select Asian territories, leaving the bulk of Revolution Medicines’ commercial fate tied to its own execution in the US and Europe.
Market Sentiment
Hedge fund ownership climbed from 85 funds to 106 in the most recent quarter, a sign that institutional conviction is building rather than fading. Short interest sits at 6.96% of float, enough to show a real bear camp exists without suggesting heavy organized skepticism. That combination points to a stock where big money is accumulating even as some short sellers push back.
Where This Leaves Investors
The tension here is straightforward. Revolution Medicines just gained a funded partner, a path into new Asian markets, and validation from a company willing to bet on its RAS(-ON) science. But the $40 billion valuation already assumes a lot of that science pays off, from pancreatic cancer through lung cancer and beyond.
While we acknowledge the risk and potential of RVMD as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than RVMD and that has 10,000% upside potential, check out our report about this cheapest AI stock.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
Disclosure: None. Follow Insider Monkey on Google News.
